Fosbretabulin: Ph I Study MCC-2016-088 started

Mateon said investigators at the University of Kentucky (Lexington, Ky.) began the open-label, U.S. Phase I Study MCC-2016-088 to evaluate IV fosbretabulin plus Afinitor everolimus for 12 weeks in abo...